On June 9, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance from the United States Patent and Trademark Office for its patent application titled 'Cryogen Flow Control.' Once granted, this patent will be in effect until 2045. A patent for this invention has already been granted in Japan, with approval pending in the European Union and other major markets.
This invention is designed to further improve cryoablation's efficiency and expand the number of indications the company can deliver in the future. Precise temperature control is crucial for efficacy and tissue safety in cryoablation procedures, and this technology achieves it by regulating cryogen flow based on sensor data. This ensures the desired temperature is reached and maintained at the probe tip, enhancing treatment effectiveness.
IceCure's CEO, Eyal Shamir, emphasized the importance of expanding intellectual property assets around its platform cryoablation technology, especially as the company awaits the FDA's marketing approval decision for ProSense® in early-stage breast cancer. This patent reinforces IceCure's position as a global leader in liquid nitrogen-based cryoablation technology and supports its continuous innovation and commercial rollout.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.